SBRT with concurrent chemoradiation in stage III NSCLC: first results of the phase I Hybrid trial

被引：0
|
作者：
Peulen, H. [1 ]
Sonke, J. J. [1 ]
Van der Bijl, E. [1 ]
Damen, E. [1 ]
Belderbos, J. [1 ]
机构：
[1] Netherlands Canc Inst, Radiat Oncol, Amsterdam, Netherlands
来源：
RADIOTHERAPY AND ONCOLOGY | 2016年 / 119卷
关键词：
D O I：
10.1016/S0167-8140(16)31526-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PV-0277
引用
收藏
页码：S129 / S129
页数：1
相关论文
共 50 条
  • [11] A randomized phase III trial of concurrent chemoradiation in locally advanced cervical cancer: preliminary results
    Veerasarn, V.
    Lorvidhaya, V.
    Suntornpong, N.
    Sukthomya, V.
    Sangruchi, S.
    Chitapanarux, I.
    Lertsanguansinchai, P.
    Khorprasert, C.
    Sookpreedee, L.
    Udompunturak, S.
    EJC SUPPLEMENTS, 2005, 3 (02): : 260 - 260
  • [12] Phase II Trial of Atezolizumab Before and After Definitive Chemoradiation for Patients with Unresectable Stage III NSCLC
    Ross, H.
    Kozono, D.
    Urbanic, J.
    Williams, T.
    Dufrane, C.
    Bara, I.
    Gandhi, M.
    Schulze, K.
    Brockman, J. M.
    Wang, X.
    Vokes, E.
    Stinchcombe, T.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2285 - S2286
  • [13] Long-term results of a prospective phase II trial of medically inoperable stage I NSCLC treated with SBRT - the Nordic experience
    Lindberg, Karin
    Nyman, Jan
    Kallskog, Vendela Riesenfeld
    Hoyer, Morten
    Lund, Jo A.
    Lax, Ingmar
    Wersall, Peter
    Karlsson, Kristin
    Friesland, Signe
    Lewensohn, Rolf
    ACTA ONCOLOGICA, 2015, 54 (08) : 1096 - 1104
  • [14] Concurrent chemoradiation with pemetrexed and cisplatin followed by consolidation pemetrexed for patients with unresectable stage III non-small cell lung cancer (NSCLC): preliminary results of a phase I study
    Cardenal, Felipe
    Arnaiz, Ma Dolores
    Moran, Teresa
    Jove, Josep
    Sole, Josep Ma
    Porta, Ruth
    Nadal, Ernest
    Brao, Isabel
    Palmero, Ramon
    Fuentes, Rafael
    Nunez, Inmaculada
    Cassinello, Alejo
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S849 - S849
  • [15] Can concurrent chemoradiation be delayed by induction chemotherapy to treat stage III NSCLC? a pooled analysis
    Garant, A.
    Guilbault, C.
    Almajed, M.
    Faria, S.
    Owen, S.
    Duclos, M.
    Ofiara, L.
    Gruber, J.
    Hirsh, V.
    Kopek, N.
    RADIOTHERAPY AND ONCOLOGY, 2015, 115 : S632 - S633
  • [16] Clinical Outcomes of Concurrent Chemoradiation vs RT alone in Elderly Patients with Stage III NSCLC
    Kim, D. Y.
    Kim, J.
    Song, C.
    Lee, J. S.
    RADIOTHERAPY AND ONCOLOGY, 2019, 133 : S397 - S397
  • [17] Concurrent versus sequential immune checkpoint inhibition in stage III NSCLC patients treated with chemoradiation
    Kaesmann, L.
    Taugner, J.
    Eze, C.
    Guggenberger, J.
    Floesch, B.
    Kenndoff, S.
    Tufman, A.
    Reinmuth, N.
    Belka, C.
    Manapov, F.
    ANNALS OF ONCOLOGY, 2022, 33 : S86 - S86
  • [18] Concurrent Chemoradiation With or Without Durvalumab in Elderly Patients With Unresectable Stage III NSCLC: Safety and Efficacy
    Lau, Sally C. M.
    Ryan, Malcolm
    Weiss, Jessica
    Fares, Aline Fusco
    Garcia, Miguel
    Schmid, Sabine
    Kuang, Shelley
    Kelly, Deirdre
    Tsao, Ming Sound
    Bradbury, Penelope A.
    Cho, Byoung Chun J.
    Sun, Alexander
    Raman, Srinivas
    Hope, Andrew
    Giuliani, Meredith
    Lok, Benjamin H.
    Bezjak, Andrea
    Liu, Geoffrey
    Leighl, Natasha B.
    Shepherd, Frances A.
    Sacher, Adrian G.
    JTO CLINICAL AND RESEARCH REPORTS, 2021, 2 (12):
  • [19] Phase II Trial of Atezolizumab Before and After Chemoradiation for Unresectable Stage III NSCLC (AFT-16): Trial in Progress
    Ross, H.
    Kozono, D.
    Urbanic, J.
    Williams, T.
    Dufrane, C.
    Bara, I.
    Gandhi, M.
    Schulze, K.
    Brockman, J. M.
    Wang, X.
    Vokes, E.
    Stinchcombe, T.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S1025 - S1025
  • [20] A phase II trial of consolidation nivolumab or nivolumab plus ipilimumab following concurrent chemoradiation in unresectable stage III NSCLC: BTCRC LUN16-081.
    Durm, Greg Andrew
    Perkins, Susan M.
    Hanna, Nasser H.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (05)
12345